secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0001157523-23-000400
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock reports FY2022 net loss of $134.5M; revenue up to $33.2M; apitegromab Phase 3 enrollment on track for 2023
--------------------------------------------------------------------------------

- Net loss of $134.5M ($2.26 per share) in FY2022; revenue $33.2M vs $18.8M prior year.
- Cash, cash equivalents, and marketable securities of $315M; expects to fund ops into 2025.
- Phase 3 SAPPHIRE trial enrollment of apitegromab on track to complete in 2023; top-line data expected 2024.
- 36-month extension data from Phase 2 TOPAZ trial expected in mid-2023; ~90% of patients remained on study.
- Appointed Tracey M. Sacco as Chief Commercial Officer in Feb 2023 to lead launch preparation for apitegromab.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000115752323000400/0001157523-23-000400-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000115752323000400/a53357191.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000400

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer